Germany Establishing a genuine European investment promotion platform is central. Understanding ourselves as strong nations is probably the most important shift needed over the next few years. Achim Hartig, Director of Foreign Direct Investment at Germany Trade & Invest (GTAI) and Chair of the OECD Network of Investment Promotion Agencies, discusses…
Germany Demand for plasma-derived medicines continues to rise, bringing renewed attention to manufacturing capacity, supply resilience and the need for stronger plasma ecosystems. As Biotest enters its next phase of growth, CEO Jörg Schüttrumpf reflects on the company’s strategic evolution, the opportunities created by its partnership with Grifols, and the role…
Europe Rock-bottom prices, regulatory red tape, and intense competition from Asia have made life difficult for Europe’s generics and biosimilar producers. Yet a handful of companies are not just surviving this squeeze but thriving in it – through diversification, geographic focus, R&D intensity, or sheer scientific specialisation. Here’s how four of…
Germany Dr Gertrud Demmler of SBK, one of Germany’s largest statutory health insurance funds, describe the EUR 18 billion funding gap facing the country’s health system, what the July 2026 GKV Contribution Rate Stabilisation Act does and doesn’t fix, why consolidation among health insurance funds is set to continue, and the…
Germany I want Wacker Biotech to be recognised for its scientific expertise, speed, collaboration, and flexibility The expectations placed on today’s CDMOs extend far beyond manufacturing capacity, demanding scientific expertise, integrated development capabilities and resilient supply networks capable of supporting increasingly complex therapies. Wacker Biotech has responded by building a distinctive…
Germany Stephan Pilsinger, Member of the German Bundestag (CSU) and Deputy Chair of the Health Committee, has publicly criticised the government’s savings package over cuts to organ-donation counselling — even as he defends the broader austerity drive as necessary. In this conversation, the practicing GP and CDU/CSU lead rapporteur on pharmaceutical…
Germany Serdar Yüksel spent two decades as a nurse before 15 years in North Rhine-Westphalia’s state parliament, and now represents the SPD on the Bundestag’s Health Committee. He discusses the jump from state to federal politics, the SPD’s push to stabilise health insurance contributions fairly across government, insurers, providers, industry and…
Germany We have set out a clear strategy, but strategy only provides direction; ultimately, trust is built through execution Europe pioneered the biosimilars industry and remains its most advanced market, yet sustaining that leadership is becoming increasingly challenging as pricing pressures, manufacturing economics and global competition reshape the sector. As Formycon…
Germany Mathias Hevert, third-generation leader of Hevert-Arzneimittel, has guided the family-owned company as CEO for more than 20 years. Founded in 1956, Hevert specialises in naturopathic medicines, including homoeopathic combination remedies, herbal products and micronutrient preparations, with revenues planned to reach EUR 40 million. The company remains focused on the German…
Germany Money follows the science, and the science here in Bavaria is excellent Ralf Huss, Chief Executive of BioM, discusses how Bavaria has built one of Europe’s leading biotechnology ecosystems by connecting researchers, entrepreneurs, investors and global pharmaceutical companies. He highlights BioM‘s role in supporting more than 500 companies, accelerating start-ups…
Germany Our ambition is not simply to bring medicines to market, but to help improve the way dermatology patients are cared for As healthcare systems come under increasing pressure to deliver better outcomes with finite resources, dermatology is evolving beyond medicines alone. Kim Abbenhaus discusses how LEO Pharma is combining scientific…
Germany Germany and Europe have every reason to remain optimistic, provided we build on the strengths we already have As Europe seeks to strengthen its pharmaceutical resilience and Germany redefines its healthcare and industrial priorities, the decisions taken today will shape the sector’s competitiveness for decades to come. Dr Kai Joachimsen,…
See our Cookie Privacy Policy Here
